Colorectal cancer: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
mNo edit summary
 
(45 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
 
'''Colorectal cancer''' probably arises from colorectal polyps.<ref name="pmid17167138">{{cite journal |author=Levine JS, Ahnen DJ |title=Clinical practice. Adenomatous polyps of the colon |journal=N. Engl. J. Med. |volume=355 |issue=24 |pages=2551–7 |year=2006 |month=December |pmid=17167138 |doi=10.1056/NEJMcp063038 |url=http://content.nejm.org/cgi/content/full/355/24/2551 |issn=}}</ref> Adenomatous polyps convert to cancers at a rate of about 1% per year.<ref name="pmid3653628">{{cite journal |author=Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL |title=Natural history of untreated colonic polyps |journal=Gastroenterology |volume=93 |issue=5 |pages=1009–13 |year=1987 |month=November |pmid=3653628 |doi= |url= |issn=}}</ref>
==Pathophysiology==
{{TOC|left}}
Colorectal cancer probably arises from colorectal polyps.<ref name="pmid17167138">{{cite journal |author=Levine JS, Ahnen DJ |title=Clinical practice. Adenomatous polyps of the colon |journal=N. Engl. J. Med. |volume=355 |issue=24 |pages=2551–7 |year=2006 |month=December |pmid=17167138 |doi=10.1056/NEJMcp063038 |url=http://content.nejm.org/cgi/content/full/355/24/2551 |issn=}}</ref> Adenomatous polyps convert to cancers at a rate of about 1% per year.<ref name="pmid3653628">{{cite journal |author=Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL |title=Natural history of untreated colonic polyps |journal=Gastroenterology |volume=93 |issue=5 |pages=1009–13 |year=1987 |month=November |pmid=3653628 |doi= |url= |issn=}}</ref>


==Treatment==
==Treatment==
{{PDQ-treatment|http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page5}}
{{PDQ-treatment|http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page5}}
===Medications===
====Aspirin====
Aspirin may reduce mortality among patients whose tumor overexpress the enzyme [[cyclooxygenase 2]] according to a [[cohort study]].<ref name="pmid19671906">{{cite journal| author=Chan AT, Ogino S, Fuchs CS| title=Aspirin use and survival after diagnosis of colorectal cancer. | journal=JAMA | year= 2009 | volume= 302 | issue= 6 | pages= 649-58 | pmid=19671906
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19671906 | doi=10.1001/jama.2009.1112 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> Cyclooxygenase 2 is expressed by most [[colorectal cancer]]s and is associated with reduced survival.<ref name="pmid15623626">{{cite journal| author=Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K| title=Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. | journal=Clin Cancer Res | year= 2004 | volume= 10 | issue= 24 | pages= 8465-71 | pmid=15623626
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15623626 | doi=10.1158/1078-0432.CCR-04-0653 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


===Medications===
====Cetuximab====
;Cetuximab
Cetuximab, an I<sub>g</sub>G1 chimeric monoclonal antibody against epidermal growth factor receptor, may help according to a [[randomized controlled trial]].<ref name="pmid18003960">{{cite journal |author=Jonker DJ, O'Callaghan CJ, Karapetis CS, ''et al'' |title=Cetuximab for the treatment of colorectal cancer |journal=N. Engl. J. Med. |volume=357 |issue=20 |pages=2040–8 |year=2007 |pmid=18003960 |doi=10.1056/NEJMoa071834}}</ref>
Cetuximab, an I<sub>g</sub>G1 chimeric monoclonal antibody against epidermal growth factor receptor, may help according to a [[randomized controlled trial]].<ref name="pmid18003960">{{cite journal |author=Jonker DJ, O'Callaghan CJ, Karapetis CS, ''et al'' |title=Cetuximab for the treatment of colorectal cancer |journal=N. Engl. J. Med. |volume=357 |issue=20 |pages=2040–8 |year=2007 |pmid=18003960 |doi=10.1056/NEJMoa071834}}</ref>


==Prognosis==
==Prognosis==
{{Image|5-Year Colorectal Cancer Relative Survival Rates By Year Dx By Cancer Site All Ages, All Races, Both Sexes 1975-2000.jpg|right|350px|5-Year Colorectal Cancer Relative Survival Rates By Year Dx By Cancer Site All Ages, All Races, Both Sexes 1975-2000. From [http://www.cancer.gov/ National Cancer Institute], [http://seer.cancer.gov/faststats/selections.php?run=runit&series=cancer&paramSubSite=&data=4&statistic=6&year=200805&race=1&sex=1&age=1&output=2&cancer[]=40#Output SEER database].}}
{{Image|5-Year Relative Survival Rates By Year Dx By Cancer Site All Ages, All Races, Both Sexes 1975-2000.jpg|right|350px|5-Year Relative Survival Rates By Year Dx By Cancer Site All Ages, All Races, Both Sexes 1975-2000.}}


===Staging information===
===Staging information===
{{PDQ-staging|http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page4}}
{{PDQ-staging|http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/page4}}
{| class="wikitable" align="right"
|+ Prognosis of colonic cancer<ref name="pmid15467030">{{cite journal| author=O'Connell JB, Maggard MA, Ko CY| title=Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. | journal=J Natl Cancer Inst | year= 2004 | volume= 96 | issue= 19 | pages= 1420-5 | pmid=15467030
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15467030 | doi=10.1093/jnci/djh275 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
! Stage!! Five-year survival rate (%)
|-
| Stage I (T1-2N0)|| 93
|-
| Stage IIA (T3N0)|| 85
|-
| Stage IIB (T4N0)|| 72
|-
| Stage IIIA (T1-2 N1)|| 83
|-
| Stage IIIB (T3-4 N1)|| 64
|-
| Stage IIIC (N2)|| 44
|-
| Stage IV|| 8
|}


==Screening==
==Screening==
{{main|colonic polyp}}
{{main|colonic polyp}}
A [[clinical practice guideline]] by the [[US Preventive Services Task Force]] has addressed colorectal cancer:<ref name="pmid18838716">{{cite journal |author= |title=Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement |journal=Annals of Internal Medicine |volume= |issue= |pages= |year=2008 |month=October |pmid=18838716 |doi= |url=http://www.annals.org/cgi/content/full/0000605-200811040-00243v1 |issn=}}</ref>
 
In the [[United States of America]], both underuse and overuse of screening occur.<ref name="pmid19349631">{{cite journal |author=Walter LC, Lindquist K, Nugent S, ''et al'' |title=Impact of age and comorbidity on colorectal cancer screening among older veterans |journal=Ann. Intern. Med. |volume=150 |issue=7 |pages=465–73 |year=2009 |month=April |pmid=19349631 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=long&pmid=19349631 |issn=}}</ref>
 
Allowing patients to choose their method of screening might be the most effective.<ref name="pmid22493463">{{cite journal| author=Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV et al.| title=Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. | journal=Arch Intern Med | year= 2012 | volume= 172 | issue= 7 | pages= 575-82 | pmid=22493463 | doi=10.1001/archinternmed.2012.332 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22493463  }} </ref>
 
===Practice guidelines===
While [[clinical practice guideline]]s are available to address screening, gastroenterologists may not follow the guidelines well.<ref name="pmid18022063">{{cite journal| author=Krist AH, Jones RM, Woolf SH, Woessner SE, Merenstein D, Kerns JW et al.| title=Timing of repeat colonoscopy: disparity between guidelines and endoscopists' recommendation. | journal=Am J Prev Med | year= 2007 | volume= 33 | issue= 6 | pages= 471-8 | pmid=18022063 | doi=10.1016/j.amepre.2007.07.039 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18022063  }} </ref>
 
====US Preventive Services Task Force====
A [[clinical practice guideline]] by the [[U.S. Preventive Services Task Force]] has addressed colorectal cancer:<ref name="pmid18838716">{{cite journal |author= |title=Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement |journal=Annals of Internal Medicine |volume= |issue= |pages= |year=2008 |month=October |pmid=18838716 |doi= |url=http://www.annals.org/cgi/content/full/0000605-200811040-00243v1 |issn=}}</ref>
* "recommends screening for colorectal cancer using fecal  occult blood testing, sigmoidoscopy, or colonoscopy in adults,  beginning at age 50 years and continuing until age 75 years."
* "recommends screening for colorectal cancer using fecal  occult blood testing, sigmoidoscopy, or colonoscopy in adults,  beginning at age 50 years and continuing until age 75 years."


Line 26: Line 59:
* "recommends against screening for colorectal cancer in  adults older than age 85 years"
* "recommends against screening for colorectal cancer in  adults older than age 85 years"


* "the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing"
* "the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing (a subsequent study found that DNA was more [[sensitivity and specificity|sensitive]] but less [[sensitivity and specificity|specific]]<ref name="pmid18838724">{{cite journal |author=Ahlquist DA, Sargent DJ, Loprinzi CL, ''et al'' |title=Stool DNA and occult blood testing for screen detection of colorectal neoplasia |journal=Ann. Intern. Med. |volume=149 |issue=7 |pages=441–50, W81 |year=2008 |month=October |pmid=18838724 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=long&pmid=18838724 |issn=}}</ref>)"


A [[clinical practice guideline]] jointly written by the [[American Cancer Society]] and other groups recommends one of:<ref>Levin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. S., et al. (2008). [http://caonline.amcancersoc.org/cgi/content/full/CA.2007.0018v1 Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-society Task Force on Colorectal Cancer, and the American College of Radiology]. CA Cancer J Clin, CA.2007.0018. {{doi|10.3322/CA.2007.0018}}.</ref>
====American College of Gastroenterology====
[[Clinical practice guideline]] published in 2009 by the American College of Gastroenterology recommends:<ref name="pmid19240699">{{cite journal| author=Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM et al.| title=American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. | journal=Am J Gastroenterol | year= 2009 | volume= 104 | issue= 3 | pages= 739-50 | pmid=19240699 | doi=10.1038/ajg.2009.104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19240699 }} [http://www.acg.gi.org/physicians/pdfs/CCSJournalPublicationFebruary2009.pdf ACG website]</ref>
* "Cancer prevention tests should be offered fi rst. The preferred CRC prevention test is colonoscopy every 10 years, beginning at age 50. (Grade 1 B) Screening should begin at age 45 years in African Americans (Grade 2 C)"
* "Cancer detection test. This test should be offered to patients who decline colonoscopy or another cancer prevention test. The preferred cancer detection test is annual FIT for blood (Grade 1 B)"
''Notes'':
Grade 2C recommendation reflects "2C/Weak recommendation, low-quality or very low-quality evidence"
 
The AGA has also issued guidance on surveillance after colonoscopy.<ref>Lieberman DA, Gastroenterology 2012 Sep; 143:844. PMID: [http://pubmed.gov/22763141 22763141]</ref>
 
====American College of Physicians====
The American College of Physicians has issued guidelines.[http://annals.org/article.aspx?articleid=1090701 Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians] 2012
 
====American Cancer Society====
''For screening'', a [[clinical practice guideline]] jointly published in 2007 by the [[American Cancer Society]] and other groups recommends one of:<ref>Levin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. S., et al. (2008). [http://caonline.amcancersoc.org/cgi/content/full/CA.2007.0018v1 Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-society Task Force on Colorectal Cancer, and the American College of Radiology]. CA Cancer J Clin, CA.2007.0018. {{doi|10.3322/CA.2007.0018}}.</ref>
* Flexible sigmoidoscopy every 5 years
* Flexible sigmoidoscopy every 5 years
* Barium enema every 5 years
* Barium enema every 5 years
Line 34: Line 80:
* Colonoscopy every 10 years
* Colonoscopy every 10 years


When polyps are found, a [[clinical practice guideline]] jointly written by the [[American Cancer Society]] and other groups states:<ref name="pmid16697750">{{cite journal |author=Winawer SJ, Zauber AG, Fletcher RH, ''et al'' |title=Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society |journal=Gastroenterology |volume=130 |issue=6 |pages=1872–85 |year=2006 |month=May |pmid=16697750 |doi=10.1053/j.gastro.2006.03.012 |url=http://www.gastrojournal.org/article/S0016-5085(06)00561-0/fulltext |issn=}}</ref>
''When polyps are found'', a [[clinical practice guideline]] jointly published in 2006 by the [[American Cancer Society]] and other groups states:<ref name="pmid16697750">{{cite journal |author=Winawer SJ, Zauber AG, Fletcher RH, ''et al'' |title=Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society |journal=Gastroenterology |volume=130 |issue=6 |pages=1872–85 |year=2006 |month=May |pmid=16697750 |doi=10.1053/j.gastro.2006.03.012 |url=http://www.gastrojournal.org/article/S0016-5085(06)00561-0/fulltext |issn=}}</ref>
* High risk polyps are 1) 3 or more synchronous adenomas, 2) adenomas ≥1 cm in diameter, or 3) villous histology or high-grade dysplasia.
* High risk polyps are 1) 3 or more synchronous adenomas, 2) adenomas ≥1 cm in diameter, or 3) villus histology or high-grade dysplasia.
* High risk polyps should have follow-up colonoscopy in 3 years
* High risk polyps should have follow-up colonoscopy in 3 years
* Low risk polyps should have repeat colonoscopy  in 5 to 10 years
* Low risk polyps should have repeat colonoscopy  in 5 to 10 years
* If no adenomas are found, follow-up evaluation should be at 10 years
* If no adenomas are found, follow-up evaluation should be at 10 years


A validation of these guidelines found:<ref name="pmid18347350">{{cite journal |author=Laiyemo AO, Murphy G, Albert PS, ''et al'' |title=Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years |journal=Ann. Intern. Med. |volume=148 |issue=6 |pages=419–26 |year=2008 |month=March |pmid=18347350 |doi= |url=http://www.annals.org/cgi/content/full/148/6/419 |issn=}}</ref>
===Evidence===
A [[cost-benefit analysis]]<ref name="10.1371/journal.pmed.1000370">Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ, 2010 Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation. PLoS Med 7(11): e1000370. {{doi|10.1371/journal.pmed.1000370}} </ref> and a [[meta-analysis]]<ref name="pmid18838718">{{cite journal |author=Whitlock EP, Lin JS, Liles E, Beil TL, Fu R |title=Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force |journal=Ann. Intern. Med. |volume=149 |issue=9 |pages=638–58 |year=2008 |month=November |pmid=18838718 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=long&pmid=18838718 |issn=}}</ref> have reviewed studies of fecal testing and colonic imaging. Immunochemical fecal occult blood (I-FOBT) tests may be the most effective.<ref name="10.1371/journal.pmed.1000370"/><ref name="pmid17310048">{{cite journal| author=Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E et al.| title=A quantitative immunochemical fecal occult blood test for colorectal neoplasia. | journal=Ann Intern Med | year= 2007 | volume= 146 | issue= 4 | pages= 244-55 | pmid=17310048 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17310048  }} </ref><ref name="pmid20360221">{{cite journal| author=Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ et al.| title=Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. | journal=BMJ | year= 2010 | volume= 340 | issue=  | pages= c1269 | pmid=20360221 | doi=10.1136/bmj.c1269 | pmc=PMC2848719 | url= }} </ref>
 
A validation of guidelines found:<ref name="pmid18347350">{{cite journal |author=Laiyemo AO, Murphy G, Albert PS, ''et al'' |title=Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years |journal=Ann. Intern. Med. |volume=148 |issue=6 |pages=419–26 |year=2008 |month=March |pmid=18347350 |doi= |url=http://www.annals.org/cgi/content/full/148/6/419 |issn=}}</ref>
* High risk adenomas - 9% of an advanced adenoma at 4 years of follow-up.
* High risk adenomas - 9% of an advanced adenoma at 4 years of follow-up.
* Low risk adenomas - 5% of an advanced adenoma at 4 years of follow-up.
* Low risk adenomas - 5% of an advanced adenoma at 4 years of follow-up.
====Fecal testing====
Feces can be tested for [[occult blood]] by either:
* Chemical reaction with [[guaiac]]
* [[Immumohistochemistry]] test for components of blood such as hemoglobin or haptoglobin. With this method, approximatelly 8% of patients will be positive after three years of yearly testing and 40% of those positive will be found to have eitehr advanced adenoma or cancer.<ref name="pmid24980879">{{cite journal| author=Kapidzic A, Grobbee EJ, Hol L, van Roon AH, van Vuuren AJ, Spijker W et al.| title=Attendance and yield over three rounds of population-based fecal immunochemical test screening. | journal=Am J Gastroenterol | year= 2014 | volume= 109 | issue= 8 | pages= 1257-64 | pmid=24980879 | doi=10.1038/ajg.2014.168 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24980879  }} </ref> The method may be the most effective<ref name="10.1371/journal.pmed.1000370"/><ref name="pmid17310048">{{cite journal| author=Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E et al.| title=A quantitative immunochemical fecal occult blood test for colorectal neoplasia. | journal=Ann Intern Med | year= 2007 | volume= 146 | issue= 4 | pages= 244-55 | pmid=17310048 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17310048  }} </ref><ref name="pmid20360221">{{cite journal| author=Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ et al.| title=Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. | journal=BMJ | year= 2010 | volume= 340 | issue=  | pages= c1269 | pmid=20360221 | doi=10.1136/bmj.c1269 | pmc=PMC2848719 | url= }} </ref> and also may be improved if patients are taking low dose [[aspirin]] to prevent [[vascular disease]].<ref name="pmid21139112">{{cite journal| author=Brenner H, Tao S, Haug U| title=Low-dose aspirin use and performance of immunochemical fecal occult blood tests. | journal=JAMA | year= 2010 | volume= 304 | issue= 22 | pages= 2513-20 | pmid=21139112 | doi=10.1001/jama.2010.1773 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21139112  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21502636 Review in: Ann Intern Med. 2011 Apr 19;154(8):JC4-10] </ref> In a [[randomized controlled trial]], immunochemical testing, as compared to colonoscopy, found a similar number of colorectal cancers but less adenomas.<ref name="pmid22356323">{{cite journal| author=Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á et al.| title=Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. | journal=N Engl J Med | year= 2012 | volume= 366 | issue= 8 | pages= 697-706 | pmid=22356323 | doi=10.1056/NEJMoa1108895 | pmc= | url= }} </ref> [[Immumohistochemistry]] testing may not have to be repeated annualy as needed by [[guaiac]]-based  testing.<ref name="pmid22387523">{{cite journal| author=van Roon AH, Goede SL, van Ballegooijen M, van Vuuren AJ, Looman CW, Biermann K et al.| title=Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. | journal=Gut | year= 2013 | volume= 62 | issue= 3 | pages= 409-15 | pmid=22387523 | doi=10.1136/gutjnl-2011-301583 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22387523  }} </ref>
* [[DNA]] DNA testing more be more sensitive than fecal immunochemical testing.<ref name="pmid24645800">{{cite journal| author=Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP et al.| title=Multitarget stool DNA testing for colorectal-cancer screening. | journal=N Engl J Med | year= 2014 | volume= 370 | issue= 14 | pages= 1287-97 | pmid=24645800 | doi=10.1056/NEJMoa1311194 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24645800  }} </ref>
====Visualization====
{| class="wikitable"
|+ Selected studies of the benefit of colorectal cancer screening<ref name="pmid22612596">{{cite journal| author=Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO et al.| title=Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy. | journal=N Engl J Med | year= 2012 | volume=  | issue=  | pages=  | pmid=22612596 | doi=10.1056/NEJMoa1114635 | pmc= | url= }} </ref><ref name="pmid21852264">{{cite journal| author=Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M et al.| title=Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial--SCORE. | journal=J Natl Cancer Inst | year= 2011 | volume= 103 | issue= 17 | pages= 1310-22 | pmid=21852264 | doi=10.1093/jnci/djr284 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21852264  }} </ref> <ref name="pmid20430429">{{cite journal| author=Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM et al.| title=Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. | journal=Lancet | year= 2010 | volume= 375 | issue= 9726 | pages= 1624-33 | pmid=20430429 | doi=10.1016/S0140-6736(10)60551-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20430429  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20956700 Review in: Ann Intern Med. 2010 Oct 19;153(8):JC4-4]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20688846 Review in: Evid Based Med. 2010 Oct;15(5):155-6] </ref><ref name="pmid8474513">{{cite journal |author=Mandel JS, Bond JH, Church TR, ''et al'' |title=Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study |journal=N. Engl. J. Med. |volume=328 |issue=19 |pages=1365–71 |year=1993 |month=May |pmid=8474513 |doi= |url=http://content.nejm.org/cgi/content/full/328/19/1365 |issn=}}</ref><ref name="pmid18853981">{{cite journal |author=Toma J, Paszat LF, Gunraj N, Rabeneck L |title=Rates of new or missed colorectal cancer after barium enema and their risk factors: a population-based study |journal=Am. J. Gastroenterol. |volume=103 |issue=12 |pages=3142–8 |year=2008 |month=December |pmid=18853981 |doi=10.1111/j.1572-0241.2008.02199.x |url=http://dx.doi.org/10.1111/j.1572-0241.2008.02199.x |issn=}}</ref><ref name="pmid8437306">{{cite journal |author=Ransohoff DF, Lang CA |title=Sigmoidoscopic screening in the 1990s |journal=JAMA |volume=269 |issue=10 |pages=1278–81 |year=1993 |month=March |pmid=8437306 |doi= |url= |issn=}}</ref><ref name="pmid1736103">{{cite journal |author=Selby JV, Friedman GD, Quesenberry CP, Weiss NS |title=A case-control study of screening sigmoidoscopy and mortality from colorectal cancer |journal=N. Engl. J. Med. |volume=326 |issue=10 |pages=653–7 |year=1992 |month=March |pmid=1736103 |doi= |url= |issn=}}</ref><ref name="pmid10365903">{{cite journal |author=Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH |title=Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I |journal=Scand. J. Gastroenterol. |volume=34 |issue=4 |pages=414–20 |year=1999 |month=April |pmid=10365903 |doi= |url= |issn=}}</ref><ref name="pmid8247072">{{cite journal |author=Winawer SJ, Zauber AG, Ho MN, ''et al'' |title=Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup |journal=N. Engl. J. Med. |volume=329 |issue=27 |pages=1977–81 |year=1993 |month=December |pmid=8247072 |doi= |url=http://content.nejm.org/cgi/content/full/329/27/19779 |issn=}}</ref><ref name="pmid19075198">{{cite journal |author=Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L |title=Association of colonoscopy and death from colorectal cancer |journal=Ann. Intern. Med. |volume=150 |issue=1 |pages=1–8 |year=2009 |month=January |pmid=19075198 |doi= |url=http://www.annals.org/cgi/content/full/150/1/1 |issn=}}</ref>
! Procedure!! Study!!Benefit!! [[Number needed to screen]]<br/>(For observational studies, assuming control rate of 1%)
|-
| Fecal occult blood annually||[[Minnesota Colon Cancer Control Study]]<ref name="pmid8474513"/><br/>[[Randomized controlled trial]]<br/>46,551 patients for 13 years ||Colorectal cancer death:<br/>[[Relative risk ratio]] 0.67<br/>[[Relative risk reduction]] 33% || align="center"|305
|-
| Double-contrast barium enema||Ontario Cancer Registry<ref name="pmid18853981"/><br/>[[Cohort study]]<br/>13,849 patients who had a DCBE 36 months prior to the diagnosis of CRC||Colorectal cancer incidence:<br/>False negative rate (1-[[Sensitivity and specificity|Sensitivity]]) 22%<br/>[[Sensitivity and specificity|Sensitivity]] 78%|| align="center"|[http://medinformatics.uthscsa.edu/calculator/calc.shtml?calc_rx_rates.shtml?eer=0.2&cer=0.9 142]
|-
| rowspan="5"|[[Sigmoidoscopy]]||PLCO trial<ref name="pmid22612596"/><br/>Sigmoidoscopy screening with one repeat at 3-5 years<br/>[[Randomized controlled trial]]<br/>154,900 for 12 years ||Colorectal cancer death:<br/>[[Relative risk ratio]] 0.74 (sig)|| align="center"|1025
|-
| SCORE trial<ref name="pmid21852264"/><br/>Sigmoidoscopy one time<br/>[[Randomized controlled trial]]<br/>34,272 subjects for 10 years ||Colorectal cancer death:<br/>[[Relative risk ratio]] 0.78 (insig)|| align="center"|1000
|-
| UK Flexible Sigmoidoscopy Trial Investigators.<ref name="pmid20430429"/><br/>Sigmoidoscopy one time<br/>[[Randomized controlled trial]]<br/>170,000 subjects for 11 years ||Colorectal cancer death:<br/>[[Relative risk ratio]] 0.67 (95% [[Confidence interval|CI]]: 0.60-0.76)|| align="center"|688
|-
| Kaiser Permanente<ref name="pmid1736103"/><br/>[[Case-control study]]<br/>261 case patients and 868 control patients for 10 years ||Colorectal cancer death:<br/>[[Odds ratio]] 0.41|| align="center"|170
|-
| Telemark Polyp Study I<ref name="pmid10365903"/><br/>[[Cohort study]]<br/>400 case patients and 399 controls for 7 to 11 years || Colorectal cancer incidence:<br/>[[Relative risk ratio]] 0.2<br/>[[Relative risk reduction]] 80% || align="center"|125
|-
| rowspan="2"|[[Colonoscopy]]||National Polyp Study<ref name="pmid8247072"/><br/>[[Cohort study]]<br/>1418 patients for 5.8 years ||Colorectal cancer incidence:<br/> [[Relative risk ratio]] 0.1<br/>[[Relative risk reduction]] 90% || align="center"|111
|-
| Ontario Cancer Registry<ref name="pmid19075198"/><br/>[[Case-control study]]<br/>10,292 case patients and 51,460 controls for 7.8 years || Colorectal cancer death:<br/>[[Odds ratio]] 0.69 || align="center"|325
|}
Visualization may be less effective in the right colon.<ref name="pmid20042716">{{cite journal| author=Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U| title=Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. | journal=J Natl Cancer Inst | year= 2010 | volume= 102 | issue= 2 | pages= 89-95 | pmid=20042716
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=20042716 | doi=10.1093/jnci/djp436 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref><ref name="pmid19075198"/>
====Capsule endoscopy====
Capsule endoscopy is less accurate than optical endoscopy.<ref name="pmid19605831">{{Cite journal
| doi = 10.1056/NEJMoa0806347
| volume = 361
| issue = 3
| pages = 264-270
| last = Van Gossum
| first = Andre
| coauthors = Miguel Munoz Navas, Inaqui Fernandez-Urien, Cristina Carretero, Gerard Gay, Michel Delvaux, Marie Georges Lapalus, Thierry Ponchon, Horst Neuhaus, Michael Philipper, Guido Costamagna, Maria Elena Riccioni, Cristiano Spada, Lucio Petruzziello, Chris Fraser, Aymer Postgate, Aine Fitzpatrick, Friedrich Hagenmuller, Martin Keuchel, Nathalie Schoofs, Jacques Deviere
| title = Capsule Endoscopy versus Colonoscopy for the Detection of Polyps and Cancer
| journal = N Engl J Med
| accessdate = 2009-07-16
| date = 2009-07-16
| url = http://content.nejm.org/cgi/content/abstract/361/3/264
| pmid = 19605831
}}</ref>
====Computed tomographic    colonography====
Laxative-free "computed tomographic colonography was accurate in detecting adenomas 10 mm or larger but less so for smaller lesions." <ref  name="pmid22586008">{{cite journal| author=Zalis ME, Blake MA, Cai  W, Hahn PF, Halpern EF, Kazam IG et al.| title=Diagnostic accuracy of  laxative-free computed tomographic colonography for detection of  adenomatous polyps in asymptomatic adults: a prospective evaluation. |  journal=Ann Intern Med | year= 2012 | volume= 156 | issue= 10 | pages=  692-702 | pmid=22586008 | doi=10.1059/0003-4819-156-10-201205150-00005 |  pmc= |  url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22586008  }} </ref>


==Prevention==
==Prevention==
===Aspirin chemoprophylaxis===
===Aspirin chemoprophylaxis===
A [[clinical practice guideline]] by the [http://www.ahrq.gov/clinic/uspstfix.htm U.S. Preventive Services Task Force (USPSTF)] recommended against taking [[aspirin]] ([http://www.ahrq.gov/clinic/3rduspstf/ratings.htm grade D recommendation]).<ref name="pmid17339621">{{cite journal |author= |title=Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement |journal=Ann. Intern. Med. |volume=146 |issue=5 |pages=361-4 |year=2007 |id=pmid=17339621 |doi=}} PMID 17339621</ref> The Task Force acknowledged that aspirin may reduce the incidence of colorectal cancer, but "concluded that harms outweigh the benefits of aspirin and NSAID use for the prevention of colorectal cancer". A subsequent [[meta-analysis]] concluded "300 mg or more of aspirin a day for about 5 years is effective in primary prevention of colorectal cancer in randomised controlled trials, with a latency of about 10 years".<ref name="pmid17499602">{{cite journal |author=Flossmann E, Rothwell PM |title=Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies |journal=Lancet |volume=369 |issue=9573 |pages=1603-13 |year=2007 |pmid=17499602 |doi=10.1016/S0140-6736(07)60747-8}} PMID 17499602</ref> However, long-term doses over 81 mg per day may increase bleeding events.<ref name="pmid17488967">{{cite journal |author=Campbell CL, Smyth S, Montalescot G, Steinhubl SR |title=Aspirin dose for the prevention of cardiovascular disease: a systematic review |journal=JAMA |volume=297 |issue=18 |pages=2018-24 |year=2007 |pmid=17488967 |doi=10.1001/jama.297.18.2018}} PMID 17488967</ref>
A [[clinical practice guideline]] by the [http://www.ahrq.gov/clinic/uspstfix.htm U.S. Preventive Services Task Force (USPSTF)] recommended against taking [[aspirin]] ([http://www.ahrq.gov/clinic/3rduspstf/ratings.htm grade D recommendation]).<ref name="pmid17339621">{{cite journal |author= |title=Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement |journal=Ann. Intern. Med. |volume=146 |issue=5 |pages=361-4 |year=2007 |id=pmid=17339621 |doi=}} PMID 17339621</ref> The Task Force acknowledged that aspirin may reduce the incidence of colorectal cancer, but "concluded that harms outweigh the benefits of aspirin and NSAID use for the prevention of colorectal cancer". Long-term doses over 81 mg per day may increase bleeding events.<ref name="pmid17488967">{{cite journal |author=Campbell CL, Smyth S, Montalescot G, Steinhubl SR |title=Aspirin dose for the prevention of cardiovascular disease: a systematic review |journal=JAMA |volume=297 |issue=18 |pages=2018-24 |year=2007 |pmid=17488967 |doi=10.1001/jama.297.18.2018}} PMID 17488967</ref>
 
Subsequent [[meta-analysis|meta-analyses]] conclude:
* "300 mg or more of aspirin a day for about 5 years is effective in primary prevention of colorectal cancer in randomised controlled trials, with a latency of about 10 years".<ref name="pmid17499602">{{cite journal |author=Flossmann E, Rothwell PM |title=Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies |journal=Lancet |volume=369 |issue=9573 |pages=1603-13 |year=2007 |pmid=17499602 |doi=10.1016/S0140-6736(07)60747-8}} PMID 17499602</ref>
* "Aspirin is effective for the prevention of colorectal adenomas in individuals with a history of these lesions."<ref name="pmid19211452">{{cite journal |author=Cole BF, Logan RF, Halabi S, ''et al'' |title=Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials |journal=J. Natl. Cancer Inst. |volume=101 |issue=4 |pages=256–66 |year=2009 |month=February |pmid=19211452 |doi=10.1093/jnci/djn485 |url=http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=19211452 |issn=}}</ref> The [[number needed to treat]] was about 33.
 
Aspirin and celecoxib may help  individuals with an increased risk of CRC according to the NIHR Health Technology Assessment programme (UK).<ref  name="pmid20594533">{{cite journal| author=Cooper K, Squires H,  Carroll C, Papaioannou D, Booth A, Logan RF et al.|  title=Chemoprevention of colorectal cancer: systematic review and  economic evaluation. | journal=Health Technol Assess | year= 2010 |  volume= 14 | issue= 32 | pages= 1-206 | pmid=20594533 |  doi=10.3310/hta14320 }} </ref>


===Calcium===
===Calcium===
Line 52: Line 161:


==References==
==References==
<references/>
{{reflist}}[[Category:Suggestion Bot Tag]]

Latest revision as of 12:39, 29 September 2024

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Colorectal_cancer&printable=yes
This editable Main Article is under development and subject to a disclaimer.

Colorectal cancer probably arises from colorectal polyps.[1] Adenomatous polyps convert to cancers at a rate of about 1% per year.[2]

Treatment

Colorectal cancer treatment information from the National Cancer Institute's Physician Data Query


Medications

Aspirin

Aspirin may reduce mortality among patients whose tumor overexpress the enzyme cyclooxygenase 2 according to a cohort study.[3] Cyclooxygenase 2 is expressed by most colorectal cancers and is associated with reduced survival.[4]

Cetuximab

Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor, may help according to a randomized controlled trial.[5]

Prognosis

5-Year Relative Survival Rates By Year Dx By Cancer Site All Ages, All Races, Both Sexes 1975-2000.

Staging information

Colorectal cancer staging information from the National Cancer Institute's Physician Data Query



Prognosis of colonic cancer[6]
Stage Five-year survival rate (%)
Stage I (T1-2N0) 93
Stage IIA (T3N0) 85
Stage IIB (T4N0) 72
Stage IIIA (T1-2 N1) 83
Stage IIIB (T3-4 N1) 64
Stage IIIC (N2) 44
Stage IV 8

Screening

For more information, see: colonic polyp.


In the United States of America, both underuse and overuse of screening occur.[7]

Allowing patients to choose their method of screening might be the most effective.[8]

Practice guidelines

While clinical practice guidelines are available to address screening, gastroenterologists may not follow the guidelines well.[9]

US Preventive Services Task Force

A clinical practice guideline by the U.S. Preventive Services Task Force has addressed colorectal cancer:[10]

  • "recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years."
  • "recommends against routine screening for colorectal cancer in adults 76 to 85 years of age. There may be considerations that support colorectal cancer screening in an individual patient."
  • "recommends against screening for colorectal cancer in adults older than age 85 years"
  • "the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing (a subsequent study found that DNA was more sensitive but less specific[11])"

American College of Gastroenterology

Clinical practice guideline published in 2009 by the American College of Gastroenterology recommends:[12]

  • "Cancer prevention tests should be offered fi rst. The preferred CRC prevention test is colonoscopy every 10 years, beginning at age 50. (Grade 1 B) Screening should begin at age 45 years in African Americans (Grade 2 C)"
  • "Cancer detection test. This test should be offered to patients who decline colonoscopy or another cancer prevention test. The preferred cancer detection test is annual FIT for blood (Grade 1 B)"

Notes: Grade 2C recommendation reflects "2C/Weak recommendation, low-quality or very low-quality evidence"

The AGA has also issued guidance on surveillance after colonoscopy.[13]

American College of Physicians

The American College of Physicians has issued guidelines.Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians 2012

American Cancer Society

For screening, a clinical practice guideline jointly published in 2007 by the American Cancer Society and other groups recommends one of:[14]

  • Flexible sigmoidoscopy every 5 years
  • Barium enema every 5 years
  • Virtual colonography (a noninvasive test based on computed tomography) every 5 years
  • Colonoscopy every 10 years

When polyps are found, a clinical practice guideline jointly published in 2006 by the American Cancer Society and other groups states:[15]

  • High risk polyps are 1) 3 or more synchronous adenomas, 2) adenomas ≥1 cm in diameter, or 3) villus histology or high-grade dysplasia.
  • High risk polyps should have follow-up colonoscopy in 3 years
  • Low risk polyps should have repeat colonoscopy in 5 to 10 years
  • If no adenomas are found, follow-up evaluation should be at 10 years

Evidence

A cost-benefit analysis[16] and a meta-analysis[17] have reviewed studies of fecal testing and colonic imaging. Immunochemical fecal occult blood (I-FOBT) tests may be the most effective.[16][18][19]

A validation of guidelines found:[20]

  • High risk adenomas - 9% of an advanced adenoma at 4 years of follow-up.
  • Low risk adenomas - 5% of an advanced adenoma at 4 years of follow-up.

Fecal testing

Feces can be tested for occult blood by either:

  • Chemical reaction with guaiac
  • Immumohistochemistry test for components of blood such as hemoglobin or haptoglobin. With this method, approximatelly 8% of patients will be positive after three years of yearly testing and 40% of those positive will be found to have eitehr advanced adenoma or cancer.[21] The method may be the most effective[16][18][19] and also may be improved if patients are taking low dose aspirin to prevent vascular disease.[22] In a randomized controlled trial, immunochemical testing, as compared to colonoscopy, found a similar number of colorectal cancers but less adenomas.[23] Immumohistochemistry testing may not have to be repeated annualy as needed by guaiac-based testing.[24]
  • DNA DNA testing more be more sensitive than fecal immunochemical testing.[25]

Visualization

Selected studies of the benefit of colorectal cancer screening[26][27] [28][29][30][31][32][33][34][35]
Procedure Study Benefit Number needed to screen
(For observational studies, assuming control rate of 1%)
Fecal occult blood annually Minnesota Colon Cancer Control Study[29]
Randomized controlled trial
46,551 patients for 13 years		 Colorectal cancer death:
Relative risk ratio 0.67
Relative risk reduction 33%		 305
Double-contrast barium enema Ontario Cancer Registry[30]
Cohort study
13,849 patients who had a DCBE 36 months prior to the diagnosis of CRC		 Colorectal cancer incidence:
False negative rate (1-Sensitivity) 22%
Sensitivity 78%		 142
Sigmoidoscopy PLCO trial[26]
Sigmoidoscopy screening with one repeat at 3-5 years
Randomized controlled trial
154,900 for 12 years		 Colorectal cancer death:
Relative risk ratio 0.74 (sig)		 1025
SCORE trial[27]
Sigmoidoscopy one time
Randomized controlled trial
34,272 subjects for 10 years		 Colorectal cancer death:
Relative risk ratio 0.78 (insig)		 1000
UK Flexible Sigmoidoscopy Trial Investigators.[28]
Sigmoidoscopy one time
Randomized controlled trial
170,000 subjects for 11 years		 Colorectal cancer death:
Relative risk ratio 0.67 (95% CI: 0.60-0.76)		 688
Kaiser Permanente[32]
Case-control study
261 case patients and 868 control patients for 10 years		 Colorectal cancer death:
Odds ratio 0.41		 170
Telemark Polyp Study I[33]
Cohort study
400 case patients and 399 controls for 7 to 11 years		 Colorectal cancer incidence:
Relative risk ratio 0.2
Relative risk reduction 80%		 125
Colonoscopy National Polyp Study[34]
Cohort study
1418 patients for 5.8 years		 Colorectal cancer incidence:
Relative risk ratio 0.1
Relative risk reduction 90%		 111
Ontario Cancer Registry[35]
Case-control study
10,292 case patients and 51,460 controls for 7.8 years		 Colorectal cancer death:
Odds ratio 0.69		 325

Visualization may be less effective in the right colon.[36][35]

Capsule endoscopy

Capsule endoscopy is less accurate than optical endoscopy.[37]

Computed tomographic colonography

Laxative-free "computed tomographic colonography was accurate in detecting adenomas 10 mm or larger but less so for smaller lesions." [38]

Prevention

Aspirin chemoprophylaxis

A clinical practice guideline by the U.S. Preventive Services Task Force (USPSTF) recommended against taking aspirin (grade D recommendation).[39] The Task Force acknowledged that aspirin may reduce the incidence of colorectal cancer, but "concluded that harms outweigh the benefits of aspirin and NSAID use for the prevention of colorectal cancer". Long-term doses over 81 mg per day may increase bleeding events.[40]

Subsequent meta-analyses conclude:

  • "300 mg or more of aspirin a day for about 5 years is effective in primary prevention of colorectal cancer in randomised controlled trials, with a latency of about 10 years".[41]
  • "Aspirin is effective for the prevention of colorectal adenomas in individuals with a history of these lesions."[42] The number needed to treat was about 33.

Aspirin and celecoxib may help individuals with an increased risk of CRC according to the NIHR Health Technology Assessment programme (UK).[43]

Calcium

A meta-analysis by the Cochrane Collaboration of randomized controlled trials published through 2002 concluded "Although the evidence from two RCTs suggests that calcium supplementation might contribute to a moderate degree to the prevention of colorectal adenomatous polyps, this does not constitute sufficient evidence to recommend the general use of calcium supplements to prevent colorectal cancer.".[44] Subsequently, one randomized controlled trial by the Women's Health Initiative (WHI) reported negative results.[45] A second randomized controlled trial reported reduction in all cancers, but had insufficient colorectal cancers for analysis.[46]

References

  1. ↑ Levine JS, Ahnen DJ (December 2006). "Clinical practice. Adenomatous polyps of the colon". N. Engl. J. Med. 355 (24): 2551–7. DOI:10.1056/NEJMcp063038. PMID 17167138. Research Blogging.
  2. ↑ Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL (November 1987). "Natural history of untreated colonic polyps". Gastroenterology 93 (5): 1009–13. PMID 3653628. [e]
  3. ↑ Chan AT, Ogino S, Fuchs CS (2009). "Aspirin use and survival after diagnosis of colorectal cancer.". JAMA 302 (6): 649-58. DOI:10.1001/jama.2009.1112. PMID 19671906. Research Blogging.
  4. ↑ Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K (2004). "Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer.". Clin Cancer Res 10 (24): 8465-71. DOI:10.1158/1078-0432.CCR-04-0653. PMID 15623626. Research Blogging.
  5. ↑ Jonker DJ, O'Callaghan CJ, Karapetis CS, et al (2007). "Cetuximab for the treatment of colorectal cancer". N. Engl. J. Med. 357 (20): 2040–8. DOI:10.1056/NEJMoa071834. PMID 18003960. Research Blogging.
  6. ↑ O'Connell JB, Maggard MA, Ko CY (2004). "Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.". J Natl Cancer Inst 96 (19): 1420-5. DOI:10.1093/jnci/djh275. PMID 15467030. Research Blogging.
  7. ↑ Walter LC, Lindquist K, Nugent S, et al (April 2009). "Impact of age and comorbidity on colorectal cancer screening among older veterans". Ann. Intern. Med. 150 (7): 465–73. PMID 19349631. [e]
  8. ↑ Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV et al. (2012). "Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies.". Arch Intern Med 172 (7): 575-82. DOI:10.1001/archinternmed.2012.332. PMID 22493463. Research Blogging.
  9. ↑ Krist AH, Jones RM, Woolf SH, Woessner SE, Merenstein D, Kerns JW et al. (2007). "Timing of repeat colonoscopy: disparity between guidelines and endoscopists' recommendation.". Am J Prev Med 33 (6): 471-8. DOI:10.1016/j.amepre.2007.07.039. PMID 18022063. Research Blogging.
  10. ↑ (October 2008) "Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. PMID 18838716. [e]
  11. ↑ Ahlquist DA, Sargent DJ, Loprinzi CL, et al (October 2008). "Stool DNA and occult blood testing for screen detection of colorectal neoplasia". Ann. Intern. Med. 149 (7): 441–50, W81. PMID 18838724. [e]
  12. ↑ Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM et al. (2009). "American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected."]. Am J Gastroenterol 104 (3): 739-50. DOI:10.1038/ajg.2009.104. PMID 19240699. Research Blogging. ACG website
  13. ↑ Lieberman DA, Gastroenterology 2012 Sep; 143:844. PMID: 22763141
  14. ↑ Levin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. S., et al. (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin, CA.2007.0018. DOI:10.3322/CA.2007.0018.
  15. ↑ Winawer SJ, Zauber AG, Fletcher RH, et al (May 2006). "Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society". Gastroenterology 130 (6): 1872–85. DOI:10.1053/j.gastro.2006.03.012. PMID 16697750. Research Blogging.
  16. ↑ 16.0 16.1 16.2 Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ, 2010 Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation. PLoS Med 7(11): e1000370. DOI:10.1371/journal.pmed.1000370
  17. ↑ Whitlock EP, Lin JS, Liles E, Beil TL, Fu R (November 2008). "Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force". Ann. Intern. Med. 149 (9): 638–58. PMID 18838718. [e]
  18. ↑ 18.0 18.1 Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E et al. (2007). "A quantitative immunochemical fecal occult blood test for colorectal neoplasia.". Ann Intern Med 146 (4): 244-55. PMID 17310048. [e]
  19. ↑ 19.0 19.1 Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ et al. (2010). "Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis.". BMJ 340: c1269. DOI:10.1136/bmj.c1269. PMID 20360221. PMC PMC2848719. Research Blogging.
  20. ↑ Laiyemo AO, Murphy G, Albert PS, et al (March 2008). "Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years". Ann. Intern. Med. 148 (6): 419–26. PMID 18347350. [e]
  21. ↑ Kapidzic A, Grobbee EJ, Hol L, van Roon AH, van Vuuren AJ, Spijker W et al. (2014). "Attendance and yield over three rounds of population-based fecal immunochemical test screening.". Am J Gastroenterol 109 (8): 1257-64. DOI:10.1038/ajg.2014.168. PMID 24980879. Research Blogging.
  22. ↑ Brenner H, Tao S, Haug U (2010). "Low-dose aspirin use and performance of immunochemical fecal occult blood tests.". JAMA 304 (22): 2513-20. DOI:10.1001/jama.2010.1773. PMID 21139112. Research Blogging. Review in: Ann Intern Med. 2011 Apr 19;154(8):JC4-10
  23. ↑ Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á et al. (2012). "Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.". N Engl J Med 366 (8): 697-706. DOI:10.1056/NEJMoa1108895. PMID 22356323. Research Blogging.
  24. ↑ van Roon AH, Goede SL, van Ballegooijen M, van Vuuren AJ, Looman CW, Biermann K et al. (2013). "Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.". Gut 62 (3): 409-15. DOI:10.1136/gutjnl-2011-301583. PMID 22387523. Research Blogging.
  25. ↑ Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP et al. (2014). "Multitarget stool DNA testing for colorectal-cancer screening.". N Engl J Med 370 (14): 1287-97. DOI:10.1056/NEJMoa1311194. PMID 24645800. Research Blogging.
  26. ↑ 26.0 26.1 Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO et al. (2012). "Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy.". N Engl J Med. DOI:10.1056/NEJMoa1114635. PMID 22612596. Research Blogging.
  27. ↑ 27.0 27.1 Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M et al. (2011). "Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial--SCORE.". J Natl Cancer Inst 103 (17): 1310-22. DOI:10.1093/jnci/djr284. PMID 21852264. Research Blogging.
  28. ↑ 28.0 28.1 Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM et al. (2010). "Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.". Lancet 375 (9726): 1624-33. DOI:10.1016/S0140-6736(10)60551-X. PMID 20430429. Research Blogging. Review in: Ann Intern Med. 2010 Oct 19;153(8):JC4-4 Review in: Evid Based Med. 2010 Oct;15(5):155-6
  29. ↑ 29.0 29.1 Mandel JS, Bond JH, Church TR, et al (May 1993). "Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study". N. Engl. J. Med. 328 (19): 1365–71. PMID 8474513. [e]
  30. ↑ 30.0 30.1 Toma J, Paszat LF, Gunraj N, Rabeneck L (December 2008). "Rates of new or missed colorectal cancer after barium enema and their risk factors: a population-based study". Am. J. Gastroenterol. 103 (12): 3142–8. DOI:10.1111/j.1572-0241.2008.02199.x. PMID 18853981. Research Blogging.
  31. ↑ Ransohoff DF, Lang CA (March 1993). "Sigmoidoscopic screening in the 1990s". JAMA 269 (10): 1278–81. PMID 8437306. [e]
  32. ↑ 32.0 32.1 Selby JV, Friedman GD, Quesenberry CP, Weiss NS (March 1992). "A case-control study of screening sigmoidoscopy and mortality from colorectal cancer". N. Engl. J. Med. 326 (10): 653–7. PMID 1736103. [e]
  33. ↑ 33.0 33.1 Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH (April 1999). "Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I". Scand. J. Gastroenterol. 34 (4): 414–20. PMID 10365903. [e]
  34. ↑ 34.0 34.1 Winawer SJ, Zauber AG, Ho MN, et al (December 1993). "Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup". N. Engl. J. Med. 329 (27): 1977–81. PMID 8247072. [e]
  35. ↑ 35.0 35.1 35.2 Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L (January 2009). "Association of colonoscopy and death from colorectal cancer". Ann. Intern. Med. 150 (1): 1–8. PMID 19075198. [e]
  36. ↑ Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U (2010). "Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study.". J Natl Cancer Inst 102 (2): 89-95. DOI:10.1093/jnci/djp436. PMID 20042716. Research Blogging.
  37. ↑ Van Gossum, Andre; Miguel Munoz Navas, Inaqui Fernandez-Urien, Cristina Carretero, Gerard Gay, Michel Delvaux, Marie Georges Lapalus, Thierry Ponchon, Horst Neuhaus, Michael Philipper, Guido Costamagna, Maria Elena Riccioni, Cristiano Spada, Lucio Petruzziello, Chris Fraser, Aymer Postgate, Aine Fitzpatrick, Friedrich Hagenmuller, Martin Keuchel, Nathalie Schoofs, Jacques Deviere (2009-07-16). "Capsule Endoscopy versus Colonoscopy for the Detection of Polyps and Cancer". N Engl J Med 361 (3): 264-270. DOI:10.1056/NEJMoa0806347. PMID 19605831. Retrieved on 2009-07-16. Research Blogging.
  38. ↑ Zalis ME, Blake MA, Cai W, Hahn PF, Halpern EF, Kazam IG et al. (2012). "Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation.". Ann Intern Med 156 (10): 692-702. DOI:10.1059/0003-4819-156-10-201205150-00005. PMID 22586008. Research Blogging.
  39. ↑ (2007) "Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement". Ann. Intern. Med. 146 (5): 361-4. pmid=17339621. [e] PMID 17339621
  40. ↑ Campbell CL, Smyth S, Montalescot G, Steinhubl SR (2007). "Aspirin dose for the prevention of cardiovascular disease: a systematic review". JAMA 297 (18): 2018-24. DOI:10.1001/jama.297.18.2018. PMID 17488967. Research Blogging. PMID 17488967
  41. ↑ Flossmann E, Rothwell PM (2007). "Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies". Lancet 369 (9573): 1603-13. DOI:10.1016/S0140-6736(07)60747-8. PMID 17499602. Research Blogging. PMID 17499602
  42. ↑ Cole BF, Logan RF, Halabi S, et al (February 2009). "Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials". J. Natl. Cancer Inst. 101 (4): 256–66. DOI:10.1093/jnci/djn485. PMID 19211452. Research Blogging.
  43. ↑ Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF et al. (2010). "Chemoprevention of colorectal cancer: systematic review and economic evaluation.". Health Technol Assess 14 (32): 1-206. DOI:10.3310/hta14320. PMID 20594533. Research Blogging.
  44. ↑ Weingarten MA, Zalmanovici A, Yaphe J (2005). "Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps". Cochrane database of systematic reviews (Online) (3): CD003548. DOI:10.1002/14651858.CD003548.pub3. PMID 16034903. Research Blogging.
  45. ↑ Wactawski-Wende J, Kotchen JM, Anderson GL, et al (2006). "Calcium plus vitamin D supplementation and the risk of colorectal cancer". N. Engl. J. Med. 354 (7): 684-96. DOI:10.1056/NEJMoa055222. PMID 16481636. Research Blogging.
  46. ↑ Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007). "Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial". Am. J. Clin. Nutr. 85 (6): 1586-91. PMID 17556697. [e]
Retrieved from "https://citizendium.org/wiki/index.php?title=Colorectal_cancer&oldid=983667"